Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00677170 · ClinicalTrials.gov registry record · Phase 1
Study of MLN4924 in Adult Patients With Nonhematologic Malignancies
A Phase 1 study of Advanced Nonhematologic Malignancies, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 3
- Study locations
NCT00677170: Completed Phase 1 study of Advanced Nonhematologic Malignancies, sponsored by Millennium Pharmaceuticals.
NCT00677170 is a Phase 1 study of Advanced Nonhematologic Malignancies that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 62 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00677170, a Phase 1 study of Advanced Nonhematologic Malignancies, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is an open-label, multicenter, Phase 1, dose escalation study of MLN4924 in adult patients with nonhematologic malignancies. This study will be the first to administer MLN4924 in humans. The patient population will consist of adults with any form of nonhematologic malignancy for which standard, curative, life prolonging, or palliative treatment does not exist or is no longer effective.
Conditions Studied
Interventions
- DRUG MLN4924
Study Locations (3)
Texas
- Cancer Therapy & Research Center at the UT Health Science Center - San Antonio
- Institute for Drug Development - San Antonio
Georgia
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2008-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
What the finished NCT00677170 record still lists
NCT00677170 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Advanced Nonhematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which MLN4924 is the first listed.
NCT00677170 reports a single indexed study location in Texas, Georgia.
Frequently Asked Questions
What is clinical trial NCT00677170 about?
NCT00677170 is a clinical study titled "Study of MLN4924 in Adult Patients With Nonhematologic Malignancies". This study is an open-label, multicenter, Phase 1, dose escalation study of MLN4924 in adult patients with nonhematologic malignancies. This study will be the first to administer MLN4924 in humans. The patient population will consist of adults with any form of nonhematologic malignancy for which sta...
What is the current status of trial NCT00677170?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2008-04. Estimated completion is 2012-12.
What conditions does trial NCT00677170 study?
This clinical trial studies the following conditions: Advanced Nonhematologic Malignancies.
What interventions are being tested in trial NCT00677170?
The interventions under investigation include: MLN4924 (DRUG).
Who is sponsoring clinical trial NCT00677170?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00677170 being conducted?
This trial has 3 study locations across Georgia, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00677170's enrollment target sits among peer trials
62 824th of 2000 higher than 1,173 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia